Delivery Order SPE2DR25D3108-SPE2DR26F1PSW
Award Date 12/1/25
Potential Completion Date 12/2/25
Potential Value $3K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, valued at $8,435.70, represents an uncompeted non-set-aside award and is scheduled for completion by July 16, 2025. The contract will be fulfilled from AmerisourceBergen's distribution...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $30,290.11 on November 20, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This firm fixed-price delivery order, with an ultimate completion date of November 21, 2025, represents a non-competitive award executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis, psoriasis, and other autoimmune conditions. This competitively awarded, non-set-aside delivery order carries a firm fixed price ceiling value of $3,021.20 with an ultimate completion date of August 25, 2025. The contract will be performed at...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication. This firm fixed-price delivery order, valued at $57,804.94, represents a non-competitive award under a larger contract vehicle and is scheduled for completion by August 8, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on November 18, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. The order, valued at $2,387.94 with a firm fixed price structure, will be fulfilled from the contractor's Conshohocken, Pennsylvania facility and is scheduled for completion by November 19, 2025. This is a non-set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Humira (adalimumab) CF Pen 40 mg/0.4 mL, a biologic medication used to treat inflammatory conditions including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This firm fixed-price delivery order, valued at $11,476.66, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. This firm fixed-price delivery order, valued at $3,770.00, represents a non-set-aside competitive award and is scheduled for completion by April 22, 2025. The product will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a biologic medication used to treat autoimmune conditions. The contract is valued at $6,817.16 and is classified as a firm fixed-price delivery order with an ultimate completion date of October 23, 2025. The award uses no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $6,400.05, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through...
- The Defense Logistics Agency awarded a delivery order valued at $53,776.82 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic medication used primarily for rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive set-aside procurement conducted under the company's existing Indefinite Delivery Contract with DLA Troop...